Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2016 20:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 25, 2016 (GLOBE...
August 24, 2016 10:03 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 24, 2016 (GLOBE...
August 23, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 23, 2016 (GLOBE...
August 19, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise

PHILADELPHIA, Aug. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its...
August 17, 2016 16:15 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split

PHILADELPHIA, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company), announced today that it will effect a 1-for-12 reverse stock split of its common stock. At the...
August 15, 2016 17:02 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016

The company continues to focus on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the...
August 15, 2016 13:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Conducts an Interview with The Wall Street Transcript

PHILADELPHIA, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted the transcript of The Wall Street Transcript interview with...
July 27, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®

PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...
July 25, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe

PHILADELPHIA, July 25, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe...
July 19, 2016 08:35 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments

Promotes Carol Smith, Ph.D., to Manager of Quality as Part of Manufacturing Optimization Retains Step Change Pharma as Advisor to Strengthen Manufacturing and Technical Infrastructure Retains...